Two sentences are both true and they do not sit comfortably together. No oral tirzepatide is approved anywhere, no clinical trial of one is registered, and the only published study that has ever put tirzepatide through a mouth was run in mice and appeared in November 2025. At the same time, 43 of the 474 sellers tracked here advertise an oral tirzepatide, at monthly prices from $119 to $419, and the oral tirzepatide board ranks them. Compounded drugs are not FDA-approved and the agency does not review them for safety, efficacy or quality before they are dispensed, which is the general case. This is a narrower one: a route for which no human absorption figure has been published for this molecule at all.
What is approved, one ingredient at a time
Drugs@FDA can be queried by active ingredient, and the answer for tirzepatide is two applications — NDA215866 and NDA217806 — under which every listed product is a solution for subcutaneous administration. No tablet, no capsule, no film. The same query run against semaglutide returns tablets for oral use under three separate applications alongside the injections, and against orforglipron returns a tablet for oral use. A nonsense ingredient string returns NOT_FOUND. The query therefore finds an oral dosage form when one has been approved, and finds none for tirzepatide.[1] Orforglipron is a different kind of molecule entirely, and what that changes is set out in the orforglipron article.
The label prints the reason
Tirzepatide is a 4813.53-dalton peptide with the empirical formula C225H348N48O68, built on the GIP sequence with aminoisobutyric acid at positions 2 and 13 and a fatty di-acid attached at position 20. The mean absolute bioavailability of that molecule by subcutaneous injection is 80%.[2] Semaglutide is smaller, at 4113.58 g/mol, and the approved tablets carry salcaprozate sodium — SNAC — an absorption enhancer coformulated specifically to get it across the stomach wall. Even with it, estimated absolute bioavailability is 0.4% to 1% for the 3 mg, 7 mg and 14 mg tablets, and 1% to 2% for the higher-strength tablets.[3]
Hold those two numbers together. Injecting the peptide delivers roughly 80% of the dose to the circulation. Swallowing a smaller peptide, formulated with a purpose-built enhancer inside an approved product, delivers roughly one part in a hundred to one part in two hundred and fifty. That is the size of the problem the mouth presents, and it is why a milligram on a tablet has never been the same thing as a milligram in a syringe — a point the approved products already illustrate in the oral versus injectable article.
The enhancer does not transfer
The mechanism behind the approved tablet was characterized in a 2018 study combining clinical and preclinical dog work. Absorption of oral semaglutide occurs in the stomach rather than the intestine, is confined to an area in close proximity to the tablet surface, and requires coformulation with SNAC; SNAC protects against enzymatic degradation through local buffering and only transiently enhances absorption. The authors state plainly that the mechanism of absorption is compound specific.[4] That last clause is the one that matters here. A delivery technology validated for one peptide is not a general solvent for peptides, and a 2025 paper developing an alternative carrier describes SNAC as “limited exclusively to semaglutide.”[5]
0.34 percent, in rats, from the compounding industry’s own laboratory
The most directly relevant published measurement was produced by the research arm of Professional Compounding Centers of America. Sprague-Dawley rats received semaglutide subcutaneously at 0.011 mg/kg, sublingually at 1 mg/kg in an anhydrous suspension, or as oral tablets at 1 mg/kg and 20 mg/kg. Sublingual dosing produced a significantly higher area under the curve than oral dosing at the same 1 mg/kg — 82.53 against 15.08 ng·h/mL, p = 0.004 — and lower variability between animals. Relative bioavailability was 0.06% for oral at 1 mg/kg, 0.16% for oral at 20 mg/kg, and 0.34% and 0.29% for sublingual prepared from tablets and from powder respectively.[6]
Read that result in both directions, because it runs both ways. The sublingual route genuinely outperformed swallowing, by more than five times on exposure, which is the strongest evidence any seller of a sublingual tablet can point to and it is real. It is also a relative bioavailability of roughly one part in three hundred against an injection — a 99.7% loss — measured in a rodent, for semaglutide rather than tirzepatide, by authors who describe their own work as proof-of-concept and call for pharmacokinetics research in humans. A five-fold improvement on a number that small is still a number that small.
For tirzepatide specifically, the record is one mouse study
In November 2025 a group reported loading semaglutide and tirzepatide onto milk-derived small extracellular vesicles and administering them orally to db/db diabetic mice, where both reduced blood glucose. The paper describes tirzepatide in this context as previously unexplored, and its endpoint was glucose lowering in animals, not a bioavailability figure in people.[5] That is the published state of oral tirzepatide science: a preclinical carrier study, four months old at the time of writing, in a strain of diabetic mouse.
The trial registry says the same thing from the other end. ClinicalTrials.gov lists 225 studies naming tirzepatide as an intervention and 598 naming semaglutide, of which 53 carry an oral-form intervention name; a nonsense string returns zero. Five tirzepatide records match oral-form search terms, and in every one of the five the word attaches to a different drug — an oral antihyperglycemic comparator, oral azelaprag, an oral placebo matched to an injection, a TLC-6740 oral solution.[7] There is no registered trial of tirzepatide given by mouth, at any phase, anywhere in the registry.
What 43 sellers are calling it
Against that, the market. Of 474 sellers tracked here, 89 list some oral GLP-1 and 43 specifically list an oral tirzepatide, advertised between $119 and $419 a month with a median of $299. The dosage forms are not one thing: seller descriptions include oral drops, dissolvable tablets, sublingual tablets taken before bed, capsules, “pills,” and chewing gum. Two products sharing the phrase “oral tirzepatide” need not be the same preparation, the same route, or the same anything, and none of them has a reference product to be compared against. What is actually inside a compounded preparation, and why that question has no single answer, is covered in the article on compounded contents.
The roster is not the only count. A cross-sectional secret shopper study conducted from August to October 2025 visited 75 brick-and-mortar weight-loss clinics and medical spas offering compounded GLP-1 receptor agonists in West Virginia and Oklahoma. Seven of them — 9.3% — reported offering oral compounded formulations, and 42 of 75 offered products combined with B vitamins.[8] Two independent censuses of two different channels put the oral share near one in ten.
The premium runs the wrong way
Forty of the 43 publish a price for both routes, which makes an internal comparison possible without leaving the seller. On 18 of the 40 the oral product is advertised above that same company’s own injectable; on 13 it is below, and on 9 the two are identical. The largest gaps are not small: one seller advertises $299 oral against $95 injectable, a ratio of 3.15, and two more sit above 2.0. The route with 80% measured bioavailability is the cheaper one at nearly half the sellers who offer both. Current advertised figures for either route can be checked against the price check tool, and the larger oral field is on the oral semaglutide board, where at least the route has an approved product standing behind it.
A daily tablet is not automatically a simpler week
The appeal of an oral route is that it removes the needle, and the approved oral semaglutide shows what replaces it. The label directs that the tablet be taken once daily on an empty stomach in the morning with no more than 4 ounces of water and no other liquid, swallowed whole without splitting, crushing, chewing or dissolving, followed by at least 30 minutes before any food, any beverage or any other oral medication.[3] That is a daily fasting window built into the schedule, in place of a weekly injection, and it exists because the absorption is fragile enough to be disturbed by a cup of coffee.
The same label carries a second warning worth reading twice: the two approved oral semaglutide products are not substitutable on a milligram-to-milligram basis with each other.[3] Two tablets of the same molecule, from the same manufacturer, both approved, do not convert by strength. A compounded sublingual tablet of a different molecule, in a different vehicle, with no published absorption data, converts to an approved injection by nothing at all.
What has not been established
No human pharmacokinetic study of oral or sublingual tirzepatide has been published. No absolute or relative bioavailability figure exists for the molecule by any route other than injection. No dose equivalence between a compounded sublingual milligram and an approved subcutaneous milligram has been measured, which means a dose ladder for the oral product cannot be derived from the approved label — it can only be asserted.
The FDA’s page on unapproved GLP-1 drugs, read in full on September 15, 2026, addresses salt forms, multiple-dose vials, warm shipping, fraudulent labels, counterfeits, adverse-event underreporting and a border alert on bulk GLP-1 ingredients. It does not mention oral, sublingual or buccal dosage forms at all.[9] An absent warning is not a clearance, and what the phrase “not FDA-approved” does and does not carry is set out in the approval-status article. How figures on this site are established before publication is described in the methodology.